Lv1
40 积分 2023-10-07 加入
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
2小时前
待确认
From backstage to the spotlight: γδT cells in cancer
2小时前
已完结
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood
15天前
已完结
Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma
16天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
1个月前
已完结
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma
1个月前
已完结
Smoldering multiple myeloma: taking the narrow over the wide path?
3个月前
已完结
High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy
3个月前
已完结
Myeloma and DNA damage
3个月前
已完结
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
4个月前
已完结
皖公网安备34019202002308
